Absorbed Radiation Dose from Radionuclidic Impurities in Several 123I-Labeled Radiopharmaceuticals

L. G. Colombetti; W. E. Barnes

doi:10.1055/s-0038-1624951

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 1976; 15(03): 152-155
DOI: 10.1055/s-0038-1624951

Originalarbeiten — Original Articles

Schattauer GmbH

Absorbed Radiation Dose from Radionuclidic Impurities in Several ¹²³I-Labeled Radiopharmaceuticals

Absorbierte Strahlendosis durch die radioaktiven Verunreinigungen der verschiedenen ¹²³J-markierten Radiopharmazeutika

L. G. Colombetti^*

¹From the Loyola University, Stritch School of Medicine and Division of Nuclear Medicine, Michael Reese Hospital and Medical Center, Chicago/Ill. 60616

,

W. E. Barnes^**

¹From the Loyola University, Stritch School of Medicine and Division of Nuclear Medicine, Michael Reese Hospital and Medical Center, Chicago/Ill. 60616

› Author Affiliations

Abstract

Summary

The radiation dose to patients from RISA, sodium iodohippurate, and rose bengal labeled with commercially available ¹²³I and its accompanying radio-impurities has been studied. The extra radiation dose to target organs was found to range from 29% to 97% that due to ¹²³I alone when the radiopharmaceutical is administered at calibration time. Additional delay in the time of administration increases the relative impurity dose.

Es wurde die Bestrahlungsdosis bei Patienten nach Gabe von RISA, Jodhippurat und Bengalrosa untersucht, welche mit dem handelsüblichen ¹²³J und dessen radioaktiven Verunreinigungen markiert waren. Die zusätzliche Strahlenbelastung der kritischen Organe wurde in einer Größenordnung von 29 bis 97 % gefunden gegenüber der alleinigen Belastung durch ¹²³J wenn die Anwendung auf die „calibration time” bezogen ist. Zusätzliche Verzögerungen bis zur Anwendungszeit lassen die relative Verunreinigungsdosis anwachsen.

Full Text

References

References
1 Colombetti L. G, Barrai R. C, Finston R. A. Experience with purity tests of ¹¹³Sn—^113mIn generators. Int. J. Appl. Rad. Isot 1969; 20: 717-724.
2 Robbins P. J, Fortman D. L. ¹²³I-Hippuran for renal function studies — preparations from available ¹²³I. J. Nucl. Med 1971; 12: 459.
3 Wellman H. N, Berke R. A, Robbins P. J, Anger R. T. Dynamic quantitative renal imaging with ¹²³I Hippuran — A possible salvation of the renogram. J. Nucl. Med 1971; 12: 405.
4 Serafini A. N, Smoak W. M, Hupf H. B, Beaver J. E, Holder J, Gilson A. J. ¹²³I-rose bengal: an improved hepatobiliary imaging agent. J. Nucl. Med 1975; 16: 629-632.
5 Kavula M. P, Rogge J. D, Anger R. T, Wellman H. N, Fitzgerald J. S. Preparation of ¹²³I rose bengal using commercially available ¹²³I. J. Nucl. Med 1975; 16: 540.
6 Drovet J, Goutheraud R, Amouch P. J, De Vernejoul P, Barritault L, Kellershohn C. Comparaison de l’utilisation de l’albumine et des macroagregats d’albumine marquee au technetium 99m et a l’Iode 123 pour l’étude de la dynamique cardio-pulmonaire. J. Biol. Med. Nucl 4 1969; 21-24.
7 De Nardo S. J, De Nardo G. L, O’Brien T, Peek N. F, Zielinski F. W, Jungerman J. A. ¹²³I fibrinogen imaging of thrombi in dogs. J. Nucl. Med 1974; 15: 487.
8 Goris M. L. ¹²³I-bromsulphalein as a liver and biliary scanning agent. J. Nucl. Med 14: 820-825. 1973;
9 Coates G, De Nardo S. J, De Nardo G. L. Pharmacokinetics of radioiodinated streptokinase. J. Nucl. Med 1973; 14: 623.
10 Meyers J, Krohn K. A, Jansholt A. L, De Nardo G. L. Preparation and chemical characterization of ¹²³I-bleomycin. J. Nucl. Med 1975; 16: 550.
11 Robinson G. D, Lee A. W. 4-Iodoantipyrine rapid, dual buffer kit method for labeling with ¹²³I. J. Nucl. Med 1975; 16: 561.
12 Sodd V. J, Scholz K. L, Blue J. W, Wellman H. N. DHEW Publ. BRH/DMRE 70—4. Cyclotron production of ¹²³I — an evaluation of the nuclear reactions which produce this isotope. 1970
13 Medi-Physics, Inc. Emeryville, California: Product page insert for ¹²³I (Nal) for oral administration.
14 Neirnckx R. D, Lambrecht R. M, Norton E. F, Wolf A. P. Quality control of radiopharmaceuticals XIV, Sodium ¹²³Iodine. Int. J. appl. Radiat 25: 387-392. 1974;
15 Johnston A. S, Baker S. I, Arnold J. E, Colombetti L. G, Pinsky S. Radionuclidic impurities in commercial ¹²³I and their influence on the dose calibrator assay of ¹²³I. J. Nucl. Med 1975; 16: 540.
16 Colombetti L. G, Johnston A. S. Absorbed radiation dose by the thyroid from radionuclidic impurities found in ¹²³I. Submitted for publication Int. J. appl. Radiat.
17 Loevinger R, Berman M. MIRD pamphlet No. 1. A schema for absorbed dose calculations for biologically distributed radionuclides. J. Nucl. Med 1968; 9 Suppl. No 1.
18 Snyder W. S, Ford M. R, Warner G. G, Watson S. B. MIRD pamphet No. 11. “S” absorbed dose per unit cumulated activity for selected radionuclides in organs. 1975
19 Beeken W. L, Voliviler W, Goldsworthy P. D, Garby L. E, Reynolds W. E, Stogsdill R, Stemler R. S. Studies of ¹³¹I albumin catabolism and distribution in normal young male adults. J. clin. Invest 1962; 41: 1312.
20 Brownell G. L, Ellett W. H, Reddy A. R. MIRD pamphlet No 3. Absorbed fractions for photon dosimetry. J. Nucl. Med 1968; 9 Suppl. No 1.
21 Blaufox M. D, Conroy M. F. Measurement of renal mean transit time of hippuran ¹³¹I with external counting. J. Nucl. Biol. Med 1968; 12: 107.
22 Waxman A. D, Leins P. A, Siemsen J. K. In vivo dynamic studies of hepatocyte function. Comput. Biomed. Res 1972; 5: 1.
23 Recommendations of the ICRP. Brit J. Radiol. Suppl 1955: 6.
24 Lushbaugh C. C, Kretchmar A, Gibbs W. Dynamic Clinical Studies with Radioisotopes. USAEC. 1963: 319.
25 McKeighen R. E. Gamma camera collimation. J. Nucl. Med 1974; 15: 1226.